Specifically, the FDA warns that compounded drugs containing Selank pose a risk for immunogenicity, a state in which the body perceives a substance as a threat and mounts a potentially life-threatening immune response against it.21 22 The FDA qualifies the risk to certain routes of administration but doesnt specify which routes, and also notes a lack of safety information concerning Selank administered to humans.21 Our relationships with peptide providers have given us additional insights into this topic, but the side effects theyve shared with us are no different from those of most therapeutic peptides weve covered ( injection site reactions , stomach discomfort , nausea , headaches , and dizziness )
Betz, A
Sphingomyelin synthase catalyzes the transfer of a phosphocholine headgroup from phosphatidylcholine to ceramide, generating sphingomyelin and 1,2-diacylglycerol
Mnimo 2
The peptide looks clear, measures correctly, and injects smoothly, but bioactivity is already degraded by 2040% before the first research application
Thiolhemin adducts are probably less prone to intercalate to the cellular membranes and cause lipid peroxidation